FIGURE 4.

Comparison of normalized ORR versus normalized proportion of patients with Grade 3+ ocular events (median and 90% prediction intervals). Data above the unity line indicate an improved benefit–risk over the approved dose of 2.5 mg/kg every 3 weeks. Arrow in regimen key indicates dose reduction following Grade 3 ocular event. Predicted ORR was based only on serum M‐protein response.

D1, Day 1; D8, Day 8; Gr3, grade 3; ORR, overall response rate; QW, once weekly; Q3W, every 3 weeks; Q6W, every 6 weeks; Q9W, every 9 weeks.